BGNE - BeiGene, Ltd.
NASDAQ
->
Healthcare
->
Biotechnology
Beijing,
China
Type: Equity
BGNE price evolution
BGNE
| (in millions $) | 31 Dec 2023 | 30 Sep 2023 | 30 Jun 2023 | 31 Mar 2023 |
|---|---|---|---|---|
| Current assets | ||||
| Cash | $3183.27 | $3078.88 | $3420.06 | $3538.8 |
| Short term investments | $2.6 | $106.99 | $105.69 | $294.06 |
| Net receivables | $358.03 | $309.08 | $299.28 | $309.63 |
| Inventory | $416.12 | $316.93 | $321.33 | $297 |
| Total current assets | $4203.41 | $4053.54 | $4401.42 | $4704.32 |
| Long term investments | $1.51 | $4.96 | ||
| Property, plant & equipment | $1419.36 | $1276.78 | $1131.36 | $1034.39 |
| Goodwill & intangible assets | $57.14 | $53.66 | $46.9 | $39.73 |
| Total noncurrent assets | $1601.86 | $1471.34 | $1327.32 | $1252.46 |
| Total investments | $2.6 | $106.99 | $107.21 | $299.02 |
| Total assets | $5805.27 | $5524.88 | $5728.74 | $5956.77 |
| Current liabilities | ||||
| Accounts payable | $315.11 | $341.86 | $266.98 | $241.36 |
| Deferred revenue | $0.3 | $0.3 | $183.31 | $222.82 |
| Short long term debt | $710.32 | $351.81 | $444.56 | $306.35 |
| Total current liabilities | $1810.11 | $1283.3 | $1405.11 | $1254.55 |
| Long term debt | $219.87 | $227.97 | $233.25 | $238.84 |
| Total noncurrent liabilities | $457.83 | $478.35 | $525.07 | $544.92 |
| Total debt | $930.18 | $579.77 | $677.81 | $545.19 |
| Total liabilities | $2267.95 | $1761.64 | $1930.18 | $1799.47 |
| Shareholders' equity | ||||
| Retained earnings | -$7962.05 | -$7594.5 | -$7809.91 | -$7428.77 |
| Other shareholder equity | -$99.45 | -$144.93 | -$143.69 | -$59.01 |
| Total shareholder equity | $3537.33 | $3763.23 | $3798.56 | $4157.31 |
| (in millions $) | 31 Dec 2023 | 31 Jan 2023 | 31 Dec 2021 | 31 Dec 2020 |
|---|---|---|---|---|
| Current assets | ||||
| Cash | $3183.27 | $3869.76 | $4376.01 | $1382.26 |
| Short term investments | $2.6 | $665.25 | $2241.96 | $3268.72 |
| Net receivables | $358.03 | $173.17 | $483.11 | $60.4 |
| Inventory | $416.12 | $282.35 | $242.63 | $89.29 |
| Total current assets | $4203.41 | $5207.08 | $7613.88 | $4960.69 |
| Long term investments | $5.28 | $6.88 | $7.75 | |
| Property, plant & equipment | $1419.36 | $955.91 | $705.04 | $448.27 |
| Goodwill & intangible assets | $57.14 | $40.62 | $46.68 | $5 |
| Total noncurrent assets | $1601.86 | $1172.21 | $1032.07 | $640.07 |
| Total investments | $2.6 | $670.53 | $2248.84 | $3276.47 |
| Total assets | $5805.27 | $6379.29 | $8645.95 | $5600.76 |
| Current liabilities | ||||
| Accounts payable | $315.11 | $294.78 | $262.4 | $231.96 |
| Deferred revenue | $0.3 | $255.89 | $407.7 | |
| Short long term debt | $710.32 | $353.01 | $449.49 | $348.91 |
| Total current liabilities | $1810.11 | $1468.53 | $1599.56 | $1075.2 |
| Long term debt | $219.87 | $243.66 | $245.15 | $213.05 |
| Total noncurrent liabilities | $457.83 | $527.41 | $803.41 | $656.32 |
| Total debt | $930.18 | $596.67 | $694.64 | $561.96 |
| Total liabilities | $2267.95 | $1995.93 | $2402.96 | $1731.51 |
| Shareholders' equity | ||||
| Retained earnings | -$7962.05 | -$7080.34 | -$4966.1 | -$3552.75 |
| Other shareholder equity | -$99.45 | -$77.42 | $17.95 | $6.94 |
| Total shareholder equity | $3537.33 | $4383.35 | $6242.99 | $3869.24 |
| (in millions $) | 31 Dec 2023 | 30 Sep 2023 | 30 Jun 2023 | 31 Mar 2023 |
|---|---|---|---|---|
| Revenue | ||||
| Total revenue | $634.41 | $781.31 | $595.26 | $447.8 |
| Cost of revenue | $105.83 | $96.31 | $95.99 | $81.79 |
| Gross Profit | $528.58 | $685 | $499.27 | $366.01 |
| Operating activities | ||||
| Research & development | $493.99 | $453.26 | $422.76 | $408.58 |
| Selling, general & administrative | $416.55 | $364.42 | $395.03 | $328.5 |
| Total operating expenses | $912.37 | $818.97 | $817.99 | $737.27 |
| Operating income | -$383.8 | -$133.97 | -$318.71 | -$371.26 |
| Income from continuing operations | ||||
| EBIT | -$367.05 | $202.69 | -$382.53 | -$352.95 |
| Income tax expense | $16.78 | $13.93 | $13.67 | $11.49 |
| Interest expense | -$16.27 | -$26.65 | -$15.07 | -$16.02 |
| Net income | ||||
| Net income | -$367.55 | $215.41 | -$381.14 | -$348.43 |
| Income (for common shares) | -$367.55 | $215.41 | -$381.14 | -$348.43 |
| (in millions $) | 31 Dec 2023 | 31 Dec 2022 | 31 Dec 2021 | 31 Dec 2020 |
|---|---|---|---|---|
| Revenue | ||||
| Total revenue | $2458.78 | $1415.92 | $1176.28 | $308.87 |
| Cost of revenue | $379.92 | $286.48 | $164.91 | $70.66 |
| Gross Profit | $2078.86 | $1129.45 | $1011.38 | $238.22 |
| Operating activities | ||||
| Research & development | $1778.59 | $1640.51 | $1459.24 | $1294.88 |
| Selling, general & administrative | $1504.5 | $1277.85 | $990.12 | $600.18 |
| Total operating expenses | $3286.59 | $2919.11 | $2450.11 | $1895.9 |
| Operating income | -$1207.74 | -$1789.66 | -$1438.73 | -$1657.68 |
| Income from continuing operations | ||||
| EBIT | -$899.85 | -$2013.52 | -$1422.83 | -$1616.58 |
| Income tax expense | $55.87 | $42.78 | -$25.23 | -$17.67 |
| Interest expense | -$74.01 | -$52.48 | $15.76 | -$2 |
| Net income | ||||
| Net income | -$881.71 | -$2003.82 | -$1413.35 | -$1596.91 |
| Income (for common shares) | -$881.71 | -$2003.82 | -$1413.35 | -$1596.91 |
| (in millions $) | 31 Dec 2023 | 30 Sep 2023 | 30 Jun 2023 | 31 Mar 2023 |
|---|---|---|---|---|
| Net income | -$367.55 | $215.41 | -$381.14 | -$348.43 |
| Operating activities | ||||
| Depreciation | $23.82 | $21.51 | $22.34 | $20.01 |
| Business acquisitions & disposals | ||||
| Stock-based compensation | $92.92 | $96 | $103.37 | $75.32 |
| Total cash flows from operations | -$221.64 | -$78.15 | -$293.89 | -$563.78 |
| Investing activities | ||||
| Capital expenditures | -$147.55 | -$167.29 | -$121.47 | -$125.58 |
| Investments | $104.33 | -$3.98 | $180.02 | $375.9 |
| Total cash flows from investing | -$62.58 | -$186.28 | $67.8 | $241.06 |
| Financing activities | ||||
| Dividends paid | ||||
| Sale and purchase of stock | $3.36 | $17.18 | $3.58 | $31.59 |
| Net borrowings | $343.69 | -$93.97 | $162.5 | -$51.46 |
| Total cash flows from financing | $347.05 | -$76.78 | $166.08 | -$19.87 |
| Effect of exchange rate | $42.27 | $0.53 | -$62.18 | $11.31 |
| Change in cash and equivalents | $105.09 | -$340.68 | -$122.19 | -$331.27 |
| (in millions $) | 31 Dec 2023 | 31 Dec 2022 | 31 Dec 2021 | 31 Dec 2020 |
|---|---|---|---|---|
| Net income | -$881.71 | -$2003.82 | -$1413.35 | -$1596.91 |
| Operating activities | ||||
| Depreciation | $87.67 | $66.28 | $46.46 | $31.79 |
| Business acquisitions & disposals | -$2.02 | |||
| Stock-based compensation | $367.62 | $303.16 | $240.71 | $183.48 |
| Total cash flows from operations | -$1157.45 | -$1496.62 | -$1298.72 | -$1283.46 |
| Investing activities | ||||
| Capital expenditures | -$561.9 | -$325.43 | -$262.94 | -$117.51 |
| Investments | $656.26 | $1546.22 | $955.51 | -$2939.33 |
| Total cash flows from investing | $60 | $1077.12 | $640.66 | -$3168.37 |
| Financing activities | ||||
| Dividends paid | ||||
| Sale and purchase of stock | $55.71 | $46.96 | $3535.38 | $4325.12 |
| Net borrowings | $360.77 | -$65.94 | $101.53 | $289.6 |
| Total cash flows from financing | $416.48 | -$18.97 | $3636.91 | $5202.83 |
| Effect of exchange rate | -$8.08 | -$69.38 | $14.04 | $18.23 |
| Change in cash and equivalents | -$689.05 | -$507.85 | $2992.88 | $769.23 |
News
Fundamentals
| Market cap | N/A |
|---|---|
| Enterprise value | N/A |
| Shares outstanding | N/A |
| Revenue | $2.46B |
|---|---|
| EBITDA | -$812.17M |
| EBIT | -$899.85M |
| Net Income | -$881.71M |
| Revenue Q/Q | 66.91% |
| Revenue Y/Y | 73.65% |
| P/E ratio | N/A |
|---|---|
| EV/Sales | N/A |
| EV/EBITDA | N/A |
| EV/EBIT | N/A |
| P/S ratio | N/A |
| P/B ratio | N/A |
| Book/Share | N/A |
| Cash/Share | N/A |
| EPS | N/A |
|---|---|
| ROA | -15.32% |
| ROE | -23.12% |
| Debt/Equity | 0.64 |
|---|---|
| Net debt/EBITDA | 1.13 |
| Current ratio | 2.32 |
| Quick ratio | 2.09 |